Sotatercept approved to treat adult patients with pulmonary arterial hypertension (PAH)

image_pdfimage_print

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved (27 December 2024) the medicine sotatercept (Winrevair) to treat pulmonary arterial hypertension (PAH). 

Leave a Reply

Your email address will not be published.